Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch
This article was originally published in The Pink Sheet Daily
Executive Summary
Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.
You may also be interested in...
Forest Credits Lexapro Growth To Less Detailing By Competitors
The antidepressant market has “normalized” following suicidality concerns, COO Goodman says.
Forest Credits Lexapro Growth To Less Detailing By Competitors
The antidepressant market has “normalized” following suicidality concerns, COO Goodman says.
Combunox's Future At Forest May Depend On Success Of New Trial Program
The future of Forest's combination pain therapy Combunox (oxycodone/ibuprofen)could depend on the success of a new product trial program launched in late September, the company suggested